The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
August 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a...
The US Food and Drug Administration has approved mitapivat tablets for the treatment of anemia in adults with alpha- or beta-thalassemia, offering a new oral option supported by randomized clinical trial...
A new analysis found that acute anemia in patients who had a heart attack is associated with a higher risk of death or recurrent myocardial infarction at 30 days.
This phase 3 study demonstrated that roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is noninferior to rHuEPO-α in improving hemoglobin levels for chemotherapy-induced anemia,...
The FDA approves the first-of-its-kind treatment for anemia caused by CKD for adults who receive dialysis following the results of a randomized clinical trial.
Previous evidence regarding this potential association has been conflicting. In a recent study, researchers aimed to clarify this relationship further.
